Yum! Brands, Inc. (NYSE:YUM) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -1.24% to $89.52. Yum! Brands, Inc. (YUM) released that its Board has permitted before reported separation of its China business, now owned by Yum China Holdings, Inc. The separation from Yum! Brands will occur following the close of business on October 31, 2016.
Yum China expects to start trading “regular way” as an independent firm on November 1 on the New York Stock Exchange under the ticker symbol “YUMC.” Yum! Brands and Yum China are predictable to start on the NYSE on October 17, under the symbol “YUM WI” for Yum! Brands and “YUMC WI” for Yum China. The Yum! Brands Board also reported an surged dividend of $0.51 per share, payable on November 4, 2016, to shareholders of record as of the close of business on October 19. The share price of YUM attracts active investors, as stock price of week volatility recorded 1.04%. The stock is going forward to its 52-week low with 40.15% and lagging behind from its 52-week high price with -2.69%.
DURECT Corporation (NASDAQ:DRRX) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -31.76% to close at $1.16 with the total traded volume of 11.34 Million shares. DURECT Corp. (DRRX) revealed that its licensee, Pain Therapeutics (PTIE) has attained a Complete Response Letter from the U.S. Food and Drug Administration for Pain Therapeutics’ New Drug Application or NDA for REMOXY ER or oxycodone extended-release capsules CII. Based on its review, the FDA has determined that the NDA cannot be agreed in its present form and specifies additional actions and data that are needed for drug authorization .
In a press release issued this morning by Pain Therapeutics, Pain Therapeutics states that “The CRL focuses on the abuse-deterrent properties of REMOXY ER and proposed drug labeling. The CRL makes no mention of clinical safety, drug efficacy, manufacturing, stability, bioequivalence or any other issues from a previous Complete Response Letter.” Pain Therapeutics is evaluating the CRL and plan additional discussions with the FDA.
The CRL specifies additional actions that are needed in order to obtain authorization of REMOXY ER with label claims against three routes of abuse (i.e., injection, inhalation and snorting). These actions may take about a year to conduct and may cost about $5 million, pending discussions with the FDA and outside clinical/regulatory consultants. The firm has institutional ownership of 50.00%, while insider ownership included 10.43%. Its price to sales ratio ended at 9.54. DRRX attains analyst recommendation of 2.30 with week performance of -30.95%.
Sally Beauty Holdings Inc. (NYSE:SBH) [Trend Analysis] climbed reacts as active mover, shares an raise 4.55% to traded at $27.82 and the percentage gap among open changing to regular change was 5.71%. The firm’s current ratio calculated as 2.50 for the most recent quarter. The firm past twelve months price to sales ratio was 1.03 and price to cash ratio remained 44.77. As far as the returns are concern, the return on equity was recorded as -72.80% and return on investment was 23.60% while its return on asset stayed at 10.90%.